WaveMan · Form 4
OrbiMed Capital GP VII LLC insider trades
> Search tickers & screens ⌘K
LIVE

OrbiMed Capital GP VII LLC insider trades

OrbiMed Capital GP VII LLC has filed 23 Form 4s with the SEC that we hold, for Passage BIO, Inc. (PASG) (10% owner), Enliven Therapeutics, Inc. (ELVN) (Director, 10% owner), Damora Therapeutics, Inc. (GLTO) (10% owner) and THRX (Director, 10% owner), among 11 companies in all. Across all of them we count 31 purchases worth $49.3M and 26 sales worth $31.7M reported on Form 4. In the last 12 months: 2 purchases ($15.0M) and 0 sales ($0). The largest single trade was a sale of 1,000,000 shares of Enliven Therapeutics, Inc. worth $22.1M, dated 2024-05-16. The first filing on our record is dated 2021-07-23 and the latest 2026-06-01.

Passage BIO, Inc. (PASG)

10% owner · 9 filings · 21 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-01-11P, purchase reported on Form 48,200$45.3K2022-01-13
2022-01-12P, purchase reported on Form 4100,000$565.0K2022-01-13
2022-01-13P, purchase reported on Form 441,800$230.7K2022-01-13
2022-01-14P, purchase reported on Form 410,300$57.7K2022-01-20
2022-01-18P, purchase reported on Form 4114,700$626.3K2022-01-20
2022-01-19P, purchase reported on Form 443,300$221.3K2022-01-20
2022-01-20P, purchase reported on Form 4369,100$2.0M2022-01-24
2022-05-03P, purchase reported on Form 4221,500$427.5K2022-05-05
2022-05-04P, purchase reported on Form 4303,500$588.8K2022-05-05
2024-09-16S, sale reported on Form 463,100$46.7K2024-09-18
2024-09-17S, sale reported on Form 4111,400$81.3K2024-09-18
2024-09-18S, sale reported on Form 425,631$18.7K2024-09-18
2024-12-04S, sale reported on Form 476,200$60.2K2024-12-06
2024-12-06S, sale reported on Form 420,903$17.1K2024-12-06
2024-12-20S, sale reported on Form 4230,321$138.2K2024-12-26
2025-01-06S, sale reported on Form 419,481$15.0K2025-01-08
2025-01-07S, sale reported on Form 452,536$37.3K2025-01-08
2025-01-08S, sale reported on Form 475,007$51.0K2025-01-08
2025-04-15S, sale reported on Form 410,326$3.9K2025-04-17
2025-04-16S, sale reported on Form 461,638$20.3K2025-04-17
2025-04-17S, sale reported on Form 477,090$25.4K2025-04-17

Enliven Therapeutics, Inc. (ELVN)

Director, 10% owner · 3 filings · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-16P, purchase reported on Form 41,666,666$10.0M2021-07-23
2024-05-16S, sale reported on Form 433,300$737.3K2024-05-20
2024-05-16S, sale reported on Form 41,000,000$22.1M2024-05-20

Damora Therapeutics, Inc. (GLTO)

10% owner · 2 filings · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-07-25S, sale reported on Form 426,700$78.0K2023-07-27
2023-07-25S, sale reported on Form 47,800$22.8K2023-07-27
2023-07-25S, sale reported on Form 44,700$13.7K2023-07-27
2023-07-31S, sale reported on Form 426,622$79.9K2023-08-02
2023-07-31S, sale reported on Form 429,700$89.1K2023-08-02
2023-07-31S, sale reported on Form 4153,078$459.2K2023-08-02

THRX

Director, 10% owner · 2 filings · 7 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-01-11P, purchase reported on Form 46,900$73.6K2022-01-13
2022-01-11P, purchase reported on Form 41,600$15.7K2022-01-13
2022-01-12P, purchase reported on Form 418,897$190.1K2022-01-13
2022-01-13P, purchase reported on Form 417,320$163.3K2022-01-13
2022-01-19P, purchase reported on Form 411,521$114.9K2022-01-21
2022-01-20P, purchase reported on Form 435,000$348.2K2022-01-21
2022-01-21P, purchase reported on Form 4111,896$1.1M2022-01-21

Arcutis Biotherapeutics, Inc. (ARQT)

10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-06-24S, sale reported on Form 435,944$766.0K2022-06-28
2022-06-24S, sale reported on Form 4306,027$6.5M2022-06-28

CIK 1900520

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

KNTE

Director, 10% owner · 1 filing · 8 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-04-28P, purchase reported on Form 460,998$155.5K2023-05-02
2023-04-28P, purchase reported on Form 460,997$155.5K2023-05-02
2023-04-28P, purchase reported on Form 4228,754$583.3K2023-05-02
2023-05-01P, purchase reported on Form 4124,545$326.3K2023-05-02
2023-05-01P, purchase reported on Form 4467,068$1.2M2023-05-02
2023-05-01P, purchase reported on Form 4124,544$326.3K2023-05-02
2023-05-02P, purchase reported on Form 458,826$157.1K2023-05-02
2023-05-02P, purchase reported on Form 4220,610$589.0K2023-05-02

Q32 Bio Inc. (QTTB)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-05-28P, purchase reported on Form 4625,000$5.0M2026-06-01
2026-05-28P, purchase reported on Form 41,250,000$10.0M2026-06-01

RPTX

Director · 1 filing · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-09-03S, sale reported on Form 4212$7.2K2021-09-08
2021-09-03S, sale reported on Form 46,985$237.5K2021-09-08
2021-09-07S, sale reported on Form 4861$29.2K2021-09-08
2021-09-07S, sale reported on Form 426$8822021-09-08

TERN

Director, 10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-08-16P, purchase reported on Form 42,470,200$6.0M2022-08-18
2022-08-16P, purchase reported on Form 4762,400$1.8M2022-08-18
2022-08-16P, purchase reported on Form 4457,400$1.1M2022-08-18

THRD

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2022-09-19P, purchase reported on Form 4300,000$5.1M2022-09-21
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1760648) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms